期刊文献+

以阳性、阴性症状为主的精神分裂症血清蛋白因子差异 被引量:12

下载PDF
导出
摘要 目的探讨以阳性、阴性症状为主的精神分裂症患者血清蛋白因子浓度变化,及其与精神病性症状之间的关系。方法采用酶联免疫吸附技术(enzyme-linked immunosorbent assay,ELISA)测定46例阳性症状为主的精神分裂症患者、37例阴性症状为主的精神分裂患者和60名正常对照者血清中神经生长因子-β(nerve growth factor-β,NGF-β)、白介素-1β(interleukin-1β,IL-1β)和髓鞘碱性蛋白(myelin basic protein,MBP)的水平,使用阳性与阴性症状量表(positive and negative syndrome scale,PANSS)评估患者精神病性症状。结果阳性症状为主的患者组和阴性症状为主的患者组NGF-β浓度低于对照组[(21.25±8.65)ng/L vs.(18.73±5.95)ng/L vs.(44.93±9.77)ng/L],而IL-1β[(61.55±21.08)ng/L vs.(79.33±25.68)ng/L vs.(24.77±8.09)ng/L]和MBP[(45.95±27.99)μg/L vs.(60.37±29.82)μg/L vs.(2.32±0.71)μg/L]浓度高于对照组,差异有统计学意义(P<0.01)。阳性症状为主的患者组IL-1β、MBP浓度低于阴性症状为主的患者组,差异有统计学意义(P<0.05)。阴性症状为主的患者组血清蛋白IL-1β(r=0.769,P<0.001)、MBP(r=0.499,P=0.002)浓度与阴性症状分呈正相关。结论阴性症状为主与阳性症状为主的精神分裂症可能有着不同的病理学机制。
出处 《中国神经精神疾病杂志》 CAS CSCD 北大核心 2015年第7期431-434,共4页 Chinese Journal of Nervous and Mental Diseases
基金 国家自然科学基金(编号:81360210)
  • 相关文献

参考文献17

  • 1Martinotti G, Di Iorio G,Marini S. Nerve growth factor andbrain-derived neurotrophic factor concentrations in schizophre-nia: a review[J]. J Biol Regul Homeost Agents, 2012,26(3):347-356.
  • 2Arolt V, Rothermundt M, Wandinger KP, et al. Decreased in vi-tro production of interferon-gamma and interleukin-2 in wholeblood of patients with schizophrenia during treatment[J]. MolPsychiatry, 2000, 5(2): 150-158.
  • 3杜蘅,唐济生.精神分裂症细胞因子及细胞因子网络的研究进展[J].中国神经精神疾病杂志,2002,28(5). 被引量:14
  • 4Xiong P, Zeng Y, Wan J, et al. The role of NGF and IL-2 serumlevel in assisting the diagnosis in first episode schizophrenia[J].
  • 5Harris LW, Pietsch S,Cheng TM, et al. Comparison of peripher-al and central schizophrenia biomarker profiles[J]. PLoS One,2012, 7(10): e46368.
  • 6Green MJ, Matheson SL, Shepherd A, et al. Brain-derived neu-rotrophic factor levels in schizophrenia: a systematic review withmeta-analysis[J]. Mol Psychiatry, 2011,16(9): 960-972.
  • 7熊鹏,吴秋霞,王继才,李国华,曾勇,张树良.精神分裂症患者血清GFAP与MBP水平的变化[J].中国神经精神疾病杂志,2013,39(1):44-47. 被引量:11
  • 8Fan Y,Abrahamsen G,Mcgrath JJ, et al. Altered cell cycle dy-namics in schizophrenia[J]. Biol Psychiatry, 2012, 71(2):129-235.
  • 9佚名.临床研究方案:方案编号WN25305 R04917838 EU-DRACT NUMBER 2010-020718-26[A].豪夫迈-罗氏有限公司,2012.
  • 10佚名.临床研究方案:方案编号WN25308 R04917838 EU-DRACT编号2010-020470-42[A].豪夫迈-罗氏有限公司,2012.

二级参考文献70

  • 1李元,肖红,高晓宁,李永平.首发精神分裂症患者血液中神经元特异性烯醇化酶和髓鞘碱性蛋白的改变[J].中华精神科杂志,2004,37(3):149-151. 被引量:10
  • 2彭代辉,江开达.胶质细胞与重性精神疾病相关研究进展[J].国际精神病学杂志,2005,32(3):177-180. 被引量:4
  • 3汪辉,李胜利,钟杏圣,陈婉清,盘圣明,李敏伟,姚航平.精神分裂症免疫功能紊乱机理的研究[J].中国神经精神疾病杂志,1996,22(5):266-268. 被引量:11
  • 4[3]Ganguli R, Brar JS, Chengappa KN, et al. Autoimmunity in schizophrenia:a review of recent tindings. Psychiatry Res, 1992,44(2): 113.
  • 5[4]Licino L, Seiby JP, Altemus M, et al. Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenia patients. Am J Psychiatry, 1993, 150(9): 1408.
  • 6[5]O' Donnell MC, Carts SV, Ward PB, et al. Increased production of interleukin-2 (IL-2) in unmedicated patients with schizophrenia and schizophreniform disorders. Psychiatry Res, 1998 16,77(1 ) :63.
  • 7[7]Petitto J, McCarthy DB, Rinker GM, et al. Modulation of behavior and neurochemical measures of forebraln dopamine function in mice by speciesspecific interleukin-2. J Neuroimmune, 1997,73(1-2): 183.
  • 8[10]Cazzullo CL,Scarone S,Grassi B,et al. Cytokines production in chronic schizophrenia patients with or without paranoid behaviour. Prog Neuropsychopharmacol Biol Psychiatry, 1998, 22(6) :947.
  • 9[11]Sirota P, Schild K, Djaldetti M, et al. Increased interleukin- 1 and interleukin-3 like activity in schizophrenic patients. Prog Neuropsy-chopharmacol Biol Psychiatry, 1995, 19( 1 ) :75.
  • 10[13]Rothermundt M, Arolt V, Weitzsch, et al. Immunological dysfunction in schizophrenia: a systematic approach. Neuropsychobiology, 1998,37 (4):186.

共引文献43

同被引文献86

引证文献12

二级引证文献45

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部